Business ❯ Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Regulatory Compliance Product Compliance Drug Efficacy Regulatory Approval Phase 3 Trials Breast Cancer Immunotherapy Obesity Treatments Amgen Phase 1 Trial

Sarepta Shares First Clinical Data From siRNA Trials in FSHD1 and DM1

The update signals a push to broaden its genetic-medicine pipeline.

Plaintiff Firms Intensify Biotech Securities Suits as Key Deadlines Near for Nektar, uniQure and REGENXBIO

Law Firms Seek Soleno Investors Ahead of May 5 Lead‑Plaintiff Deadline

Law Firms Urge Nektar Investors to Seek Lead Role in Securities Suit Over REZOLVE-AA Trial

Soleno Therapeutics Sued in Federal Securities Class Action Over DCCR Safety and Launch Claims

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

Vistagen Hit With Securities Class Actions After Phase 3 Miss as Investors Face March 16 Deadline

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Samsung Epis Targets 20 Biosimilars by 2030, Adds Six Candidates and Readies First ADC Trial

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

Hagens Berman and Pomerantz Launch Probes Into Rezolute After Phase 3 Ersodetug Failure

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

aTyr Investors Face Dec. 8 Deadline in Securities Suits Over Efzofitimod Trial Failure

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

AstraZeneca Posts Record Quarter as Cancer Drugs Lift Sales, Keeps Guidance

FDA Setback Puts uniQure’s Huntington’s Gene Therapy Filing in Doubt

Viking Therapeutics Jumps After Wider Q3 Loss as R&D Ramp Signals Obesity-Drug Progress

Praxis Drug Succeeds in Two Phase 3 Essential Tremor Trials, FDA Filing Planned

Law Firms Urge Jasper Therapeutics Investors to Seek Lead‑Plaintiff Role Before Nov. 18 Deadline

Pfizer Lifts 2025 EPS Outlook, Targets $7.7 Billion in Savings as Dividend Draws Interest